EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY 4.0

Efficacy of cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn’s disease—A prospective nationwide multicenter cohort study

Christopher Dawoud, Kerstin Melanie Widmann, Sascha Czipin, Michael Pramhas, Martina Scharitzer, Anton Stift, Felix Harpain, Stefan Riss

Wiener klinische Wochenschrift · 2024

DOI: 10.1007/s00508-023-02283-4 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Wiener klinische Wochenschrift, 2024. Verfasst von Christopher Dawoud und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Division of Visceral Surgery, Medical University Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. Hauptthemen laut MEDLINE: Crohn Disease, Rectal Fistula. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Vienna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The use of mesenchymal stem cells is considered a novel and promising therapeutic option for patients with perianal fistulizing Crohn’s disease; however, data on its clinical application remain scarce. This multicenter nationwide study aimed to assess the clinical efficacy of mesenchymal stem cells in closing complex anal fistulas.

Methods

In this study 14 Crohn’s disease patients (3 males, 11 females) with complex anal fistulas treated in 3 tertiary hospitals in Austria were included between October 2018 and April 2021. Injection of 120 million allogeneic expanded adipose-derived mesenchymal stem cells (Cx601—darvadstrocel) was performed in each patient. Closure of the external fistula opening without secretion by external manual compression was defined as treatment success.

Results

The median age of the patient population at the time of surgery was 32 years (range 26–53 years) with a median body mass index of 21.7 kg/m 2 (range 16.7–26.6 kg/m 2 ). Of the patients 12 (86%) received monoclonal antibodies (infliximab, adalimumab, ustekinumab, vedolizumab) at the time of surgery. The median number of complex fistulas was 1.4 (range 1–2), The median operative time was 20 min (range 6–50 min) with no perioperative complications. After a median follow-up of 92 weeks, we found successful fistula closure in 57.1% ( n = 8) of treated patients. The perianal disease activity index did not improve significantly from initially 7 to a median of 6 after 52 weeks ( p = 0.495).

Conclusion

Darvadstrocel is a safe, minimally invasive surgical technique without significant perioperative complications. Clinical success can be expected in about half of the treated patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseRectal FistulaHumansMaleFemaleAdultMiddle AgedProspective StudiesTreatment OutcomeAustriaMesenchymal Stem Cell TransplantationCohort Studies

Stichwörter der Autor:innen

Anal fistulaComplex fistulaFistula remissionPerianal fistulizing Crohn’s diseaseStem cell therapy

Autor:innen und Institutionen

  • Department of General Surgery, Division of Visceral Surgery, Medical University Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
  • Department of Visceral, Transplant and Thoracic Surgery, Centre for Operative Medicine, Medical University of Innsbruck, Innsbruck, Austria.
  • First Surgical Department, Klinik Landstraße, Vienna, Austria.
  • Department of Biomedical Imaging and Image-Guided Therapy, Medical University Vienna, Vienna, Austria.
  • Department of General Surgery, Division of Visceral Surgery, Medical University Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. stefan.riss@meduniwien.ac.at.

Förderung

  • Medical University of Vienna

Zitieren

APA

Dawoud, C., Widmann, K. M., Czipin, S., Pramhas, M., Scharitzer, M., Stift, A., Harpain, F., & Riss, S. (2024). Efficacy of cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn’s disease—A prospective nationwide multicenter cohort study. Wiener klinische Wochenschrift. https://doi.org/10.1007/s00508-023-02283-4

Vancouver

Dawoud C, Widmann KM, Czipin S, Pramhas M, Scharitzer M, Stift A, et al. Efficacy of cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn’s disease—A prospective nationwide multicenter cohort study. Wiener klinische Wochenschrift. 2024. doi:10.1007/s00508-023-02283-4

BibTeX
@article{Dawoud2024,
  author = {Dawoud, Christopher and Widmann, Kerstin Melanie and Czipin, Sascha and Pramhas, Michael and Scharitzer, Martina and Stift, Anton and Harpain, Felix and Riss, Stefan},
  title = {Efficacy of cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn’s disease—A prospective nationwide multicenter cohort study},
  journal = {Wiener klinische Wochenschrift},
  year = {2024},
  doi = {10.1007/s00508-023-02283-4}
}
Kostenlos starten →